This meta-analysis reports that upfront RT significantly increased OS compared with EGFR-TKI alone, especially when upfront SRS is applied to the treatment of limited BMs in EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.